Tailored Life Sciences Insurance

Most leaders tune out when they hear “tax credit.” That may be a mistake. R&D credits have quietly expanded and can unlock real strategic value for life sciences companies. I’ve spent enough time in boardrooms and leadership meetings to know that when someone says “tax credit,” most ears glaze over. It’s the kind of topic that lands squarely in the important but not urgent bucket. And yet, the conversations I’ve been having lately with experts in the life sciences are making me rethink that instinct.

Scientists have studied Alzheimer’s disease for over a century, since Alois Alzheimer’s initial description of brain abnormalities in a patient with presenile dementia. Today, amyloid‑beta plaques and tau tangles are recognized as hallmarks of the disease, though its causes are complex and multifactorial.

In 2023, Berkley Life Sciences published a blog post titled PFAS “Forever Chemicals” in Medical and Life Sciences Products – Who Should Be Worried?. At that time, most per- and polyfluoroalkyl substances (PFAS) litigation to date focused on lawsuits against PFAS manufacturers, alleging personal injury from PFAS exposure. Since then, PFAS litigation has evolved, and both the U.S. Food and Drug Administration (FDA) and European Chemicals Agency (ECHA) have issued updates, warranting a fresh look at this topic.